Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma

J Clin Oncol. 2010 May 1;28(13):e205-7; author reply e208. doi: 10.1200/JCO.2009.27.1114. Epub 2010 Feb 16.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / secondary
  • Drug Approval*
  • Evidence-Based Medicine
  • Humans
  • Platinum Compounds / administration & dosage
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Urologic Neoplasms / drug therapy*
  • Urologic Neoplasms / pathology
  • Vinblastine / analogs & derivatives*
  • Vinblastine / therapeutic use

Substances

  • Antineoplastic Agents, Phytogenic
  • Platinum Compounds
  • vinflunine
  • Vinblastine